EMILY JOHNSON: Open Payments
NPI 1053175935 · NEW LONDON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,324 in 50 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $276 · 2025 $1,324
Food & beverage: $1,324
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $323 |
| Madrigal Pharmaceuticals | 6 | $266 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $120 |
| Ardelyx, Inc. | 5 | $103 |
| Phathom Pharmaceuticals, Inc. | 1 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $95 |
| QOL Medical, LLC | 2 | $87 |
| Novo Nordisk Inc | 2 | $53 |
| GENZYME CORPORATION | 2 | $51 |
| Lilly USA, LLC | 2 | $44 |
Products named: REZDIFFRA, RINVOQ, XIFAXAN, IBSRELA, VOQUEZNA, Sucraid, SKYRIZI, ENTYVIO.
Industry payments across CT — which companies pay providers there.
